Glenmark Pharmaceuticals on Monday said its US-based subsidiary has introduced a generic medication used for eye itching. Glenmark Therapeutics Inc, USA has launched Olopatadine Hydrochloride Ophthalmic Solution (OTC) in the US market, the Mumbai-based drug maker said in a regulatory filing. Fabio Moreno, Head of OTC Sales & Marketing, Glenmark Pharmaceuticals Inc, said the launch of Olopatadine Ophthalmic Solution (USP, 0.1 per cent), addresses a growing demand for a new supplier in this category. "This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers," Moreno said.
The brokerage has increased its target multiple from 44x to 46x to factor in the company's market share gain in room AC and improvement in EMP profitability.
